Table 3. Exploratory Analyses (only resected patients included).
Outcome | |||
---|---|---|---|
| |||
Cavitation (N=7) | No cavitation (N=34) | p-value | |
| |||
Downstaged | 5 (71%) | 14 (41%) | |
Not downstaged | 2 (29%) | 20 (59%) | 0.22 |
| |||
Nodal down-staged | 5 (83%) | 12 (46%) | |
Not downstaged | 1 (17%) | 14 (54%) | 0.18 |
| |||
Path response ≥90% | 4 (57%) | 7 (21%) | |
<90% | 3 (43%) | 27 (79%) | 0.069 |
| |||
3-yr RFS all | 63% | 53% | 0.43 |
3-yr RFS IIIA | 57% | 39% | 0.32 |
| |||
3-yr OS all | 60% | 60% | 0.83 |
3-yr OS IIIA | 57% | 44% | 0.48 |
| |||
KRAS-mutant (N=10) | KRAS wild-type (N=31) | ||
| |||
Downstaged | 5 (50%) | 14 (45%) | |
Not downstaged | 5 (50%) | 17 (55%) | 1.0 |
| |||
Nodal down-staged | 5 (63%) | 12 (50%) | |
Not downstaged | 3 (37%) | 12 (50%) | 0.69 |
| |||
Path response ≥90% | 0 (0%) | 11 (35%) | |
<90% | 10 (100%) | 20 (65%) | 0.039 |
| |||
3-yr RFS all | 35% | 65% | 0.14 |
3-yr RFS IIIA | 17% | 56% | 0.096 |
| |||
3-yr OS all | 33% | 72% | 0.036 |
3-yr OS IIIA | 17% | 61% | 0.068 |